The SIWV tetrapeptide derived from annexin-A3 specifically targets glioblastoma tissue and significantly improved drug delivery in a mouse brain tumor model.
4 amino acidsthe remarkably simple SIWV peptide specifically targets glioblastoma and improves chemotherapy delivery in a mouse model
What the researchers found
The SIWV peptide was identified from an isoform of annexin-A3, a human membrane-interacting protein. It showed remarkable specificity for glioblastoma tissue both in cell cultures and in living mice.
The peptide enters cells through a caveolin-mediated endocytosis pathway, confirmed through receptor inhibition and genetic knockdown experiments.
When grafted onto porous silicon nanoparticles loaded with the cancer drug SN-38, SIWV-targeted nanoparticles showed significantly better tumor targeting than scrambled-peptide controls in a mouse brain tumor model. The treatment also showed statistically significant anti-tumor efficacy (P < 0.05) compared to free SN-38.
Why it matters
Glioblastoma is the most aggressive brain tumor, and getting drugs past the blood-brain barrier to reach these tumors is one of the biggest challenges in oncology. A peptide that specifically homes to glioblastoma tissue could dramatically improve drug delivery.
The fact that SIWV is only four amino acids long makes it relatively simple to manufacture and attach to various drug carriers.
The numbers in context
4-amino-acid peptide (SIWV); P < 0.05 vs free SN-38; enhanced targeting vs scrambled control
How the study worked
This was a preclinical study using both cell cultures and a mouse xenograft model of glioblastoma. Researchers identified the SIWV sequence from annexin-A3, characterized its cell entry mechanism through inhibition studies, and tested therapeutic efficacy by loading porous silicon nanoparticles with SN-38 and grafting them with SIWV via a PEG linker.
Who was studied
Glioblastoma xenograft mice and cell cultures
What this study cannot tell us
This was tested in a mouse xenograft model, which uses human tumor cells implanted into immune-compromised mice. This does not fully replicate the human brain tumor environment or immune system.
The study did not test whether SIWV crosses the blood-brain barrier when tumors are intact, which is critical for clinical translation.
How to read the evidence
Preliminary evidence from a mouse xenograft model. Promising but immune-compromised mice may not reflect human treatment response.
When this study was published
Published in 2020. Brain tumor targeting peptides remain an active area of research.
The bigger picture
Glioblastoma is the most aggressive brain cancer with poor response to chemotherapy, largely because drugs cannot reach the tumor effectively. A simple 4-amino-acid homing peptide that crosses the blood-brain barrier and targets tumor tissue could transform drug delivery for brain cancers.
Questions still open
- Does SIWV cross the intact blood-brain barrier or only the disrupted barrier around tumors?
- Could SIWV be used to deliver other drugs or imaging agents to brain tumors?
- Would this work in immunocompetent mice with intact immune responses?
Common questions
Why is drug delivery to brain tumors so difficult?
Could a peptide this small really be effective?
Read the original research
A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.
Nanoscale horizons, 5(8), 1213-1225
Citation
Kang, Rae Hyung; Jang, Jeong-Eun; Huh, Eugene; Kang, Seong Jae; Ahn, Dae-Ro; Kang, Jae Seung; Sailor, Michael J; Yeo, Seung Geun; Oh, Myung Sook; Kim, Dokyoung; Kim, Hyo Young. (2020). A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.. Nanoscale horizons, 5(8), 1213-1225. https://doi.org/10.1039/d0nh00077a